| P2093 | author name string | Marco Colleoni | |
| | Emilia Montagna | |
| P2860 | cites work | PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro | Q21195212 |
| | ErbB receptors: from oncogenes to targeted cancer therapies | Q24683709 |
| | Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 |
| | Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer | Q27851691 |
| | Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 |
| | ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer | Q28678776 |
| | Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer | Q29547699 |
| | ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling | Q33886341 |
| | Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer. | Q34578377 |
| | Adjuvant trastuzumab in HER2-positive breast cancer | Q35710898 |
| | Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation | Q35889621 |
| | Letrozole in the neoadjuvant setting: the P024 trial | Q36026549 |
| | Estrogen-receptor biology: continuing progress and therapeutic implications | Q36065443 |
| | Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer | Q36279700 |
| | Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes? | Q36551617 |
| | The ErbB2 signaling network as a target for breast cancer therapy | Q36583512 |
| | Mechanisms of Endocrine Resistance in Breast Cancer | Q36851417 |
| | Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens | Q37380452 |
| | Targeting HER2 for the treatment of breast cancer | Q38317974 |
| | Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer | Q38743961 |
| | Palbociclib and Letrozole in Advanced Breast Cancer | Q39105459 |
| | AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer | Q39741482 |
| | PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. | Q39767744 |
| | Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models | Q39771295 |
| | Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance | Q40536641 |
| | Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer | Q40544950 |
| | The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. | Q40571024 |
| | Epidermal growth factor-related peptides activate distinct subsets of ErbB receptors and differ in their biological activities | Q41216128 |
| | Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. | Q41655720 |
| | The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand. | Q41717039 |
| | Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation | Q42442143 |
| | Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer | Q43270036 |
| | Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. | Q45044547 |
| | Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study | Q46256397 |
| | Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer | Q46799296 |
| | MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer | Q47716239 |
| | 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. | Q48055457 |
| | Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study | Q48540914 |
| | Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors. | Q51514665 |
| | The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. | Q54115075 |
| | Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial. | Q54566127 |
| | Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy. | Q54977570 |
| | 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)† | Q56910818 |
| | Targeted agents for HER2-positive breast cancer in older adults: current and future perspectives | Q57106169 |
| | Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort | Q57579888 |
| | The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers | Q80081696 |
| | Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM | Q84592604 |
| | Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial | Q87702640 |
| | Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic | Q89648608 |
| | First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase | Q90938965 |
| | Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer | Q92040348 |
| P921 | main subject | metastatic breast cancer | Q12859063 |
| P304 | page(s) | 1758835919894105 | |
| P577 | publication date | 2019-12-16 | |
| P1433 | published in | Therapeutic advances in medical oncology | Q26842113 |
| P1476 | title | Hormonal treatment combined with targeted therapies in endocrine-responsive and HER2-positive metastatic breast cancer | |
| P478 | volume | 11 | |